

**URGENT**  
**PRESS RELEASE**



Wockhardt Limited  
Wockhardt Towers  
Bandra Kurla Complex  
Bandra (East), Mumbai 400  
051, India  
Tel.: +91 22 2653 4444  
Fax: +91 22 2653 4242  
Website: [www.wockhardt.com](http://www.wockhardt.com)

---

## Wockhardt's Q2 Results 2009

Consolidated Sales at Rs. 954 crore  
Operating Profit (EBIDTA) at Rs. 168 crore

Mumbai, 30 Jul, 2009

Pharmaceutical and biotechnology major Wockhardt Limited today announced a 4.8% growth in consolidated sales revenues to stand at Rs. 954 crore for the second quarter ended June 30, 2009 over the corresponding quarter of 2008. Operating profit (EBIDTA) is Rs. 168 crore. Net loss at Rs. 190 crore is due to exceptional items like interest, exchange rate fluctuation and MTM losses.

### **India Business:**

As per ORG-IMS for Q2-2009, Wockhardt's India business grew by 9%; thereby improving its ranking to the 15th position. Overall 8 brands featured in the list of 'Top 300' brands of the industry with 2 brands in the 'Top 100'. The biotech portfolio has been enriched with the launch of Glaritus, a recombinant long-acting human insulin analogue – glargine.

### **Europe Business:**

Wockhardt UK continues to lead the way with a growth of 11% compared to the industry growth of only 4% in Q2-2009. Hospital products in UK grew by 29% and exports recorded a 39% growth. Two products in the field of Antibiotics and Oncology were launched. Wockhardt UK's Contract Manufacturing Organisation signed an agreement for development and supply for anti-diabetics. Pinewood Healthcare in Ireland and Negma Laboratories in France consolidates and maintains their sales. Wockhardt's Europe business grew by 3% in Q2-2009.

### **USA Business:**

The US business grew by 24% in Q2-2009 and it currently contributes 19% to Wockhardt's overall revenues. There were 7 ANDA approvals received till the end of Q2-2009 with 64 products being currently marketed in the US.

### **About Wockhardt**

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.

---

For more information, visit [www.wockhardt.com](http://www.wockhardt.com)

Corporate Relations Department